UNIVERSITY OF MISSISSIPPI MEDICAL
- Type
- Teaching hospital
- Where
- JACKSON, MS
- Medicare CCN
- 250001
- Received
- $2,130,312 in 581 records, 2019 ($179,875 general, $1,950,436 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 179 | $179,875 |
| 2019 | Research payment | 402 | $1,950,436 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 402 | $1,950,436 |
| Grant | 48 | $63,540 |
| Space rental or facility fees (teaching hospital only) | 46 | $49,504 |
| Education | 34 | $22,416 |
| Gift | 14 | $17,527 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 16 | $12,580 |
| Travel and Lodging | 3 | $8,467 |
| Royalty or License | 12 | $3,277 |
| Food and Beverage | 5 | $2,169 |
| Charitable Contribution | 1 | $391 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Sirona Dental, Inc. | $9,020 | Grant | In-kind items and services | CEREC Device, Dental Equipment | 2019 | |
| 2019-12-31 | Stryker Corporation | $3,797 | Gift | In-kind items and services | NSE - HIGH SPEED DRILLS Device, NEURO SPINE ENT | 2019 | |
| 2019-12-31 | Stryker Corporation | $3,016 | Gift | In-kind items and services | SURG - SYSTEM 7 Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $2,916 | Gift | In-kind items and services | SURG - SYSTEM 7 Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $2,916 | Gift | In-kind items and services | SURG - SYSTEM 7 Device, SURGICAL | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $1,686 | Research payment | In-kind items and services | A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Anti | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $1,349 | Research payment | In-kind items and services | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclon | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $514 | Research payment | In-kind items and services | MEDI8897 RSV mAb-D5290C00003 Phase 2 / 2b Clinical Trial | 2019 | |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $413 | Research payment | Cash or cash equivalent | UMississippi2018MRIPR1104Fatemi | 2019 | |
| 2019-12-31 | AstraZeneca UK Limited | $391 | Research payment | In-kind items and services | BYDUREON Drug, Cardiovascular and Metabolism | A Phase 3 Double Blind Placebo Controlled Randomized Multi Center Study To Assess the Safety and Efficacy of Exenatide O | 2019 |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $391 | Charitable Contribution | In-kind items and services | 2019 | ||
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $103 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $95 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Stryker Corporation | $0 | Gift | Cash or cash equivalent | NONE Device, NONE | 2019 | |
| 2019-12-31 | Stryker Corporation | $0 | Gift | Cash or cash equivalent | NONE Device, NONE | 2019 | |
| 2019-12-26 | United Therapeutics Corporation | $357 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A MULTICENTER RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROST | 2019 |
| 2019-12-20 | Janssen Research & Development, LLC | $15,500 | Research payment | Cash or cash equivalent | A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction | 2019 | |
| 2019-12-19 | Shire North American Group Inc | $57,995 | Research payment | Cash or cash equivalent | A PHASE 2B, MULTICENTER, RANDOMIZED, OPEN-LABEL, CONTROLLED, 3-ARM STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF | 2019 | |
| 2019-12-19 | Shire North American Group Inc | $33,923 | Research payment | Cash or cash equivalent | A PHASE 2B, MULTICENTER, RANDOMIZED, OPEN-LABEL, CONTROLLED, 3-ARM STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF | 2019 | |
| 2019-12-19 | Shire North American Group Inc | $22,953 | Research payment | Cash or cash equivalent | A PHASE 2B, MULTICENTER, RANDOMIZED, OPEN-LABEL, CONTROLLED, 3-ARM STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF | 2019 | |
| 2019-12-18 | AMAG Pharmaceuticals, Inc. | $7,000 | Research payment | Cash or cash equivalent | A Phase 2b3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safet | 2019 | |
| 2019-12-18 | Gilead Sciences, Inc. | $2,966 | Research payment | Cash or cash equivalent | Cayston Drug, RESP | Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg | 2019 |
| 2019-12-18 | Intercept Pharmaceuticals, Inc. | $1,160 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-12-13 | Medical Device Business Services, Inc. | $18,078 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi-Center Clinical Evaluation of the ATTUNE Revision System in Complex Primary Total Knee Arthroplasty | 2019 |
| 2019-12-13 | W. L. Gore & Associates, Inc. | $982 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Gore Research and Development | 2019 |
| 2019-12-12 | Incyte Corporation | $10,661 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-12 | TESARO, Inc. | $1,639 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | CROSSOVER STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF NIRAPARIB TABLET COMPARED TO NIRAPARIB CAPSULE | 2019 |
| 2019-12-11 | United Therapeutics Corporation | $6,817 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DI | 2019 |
| 2019-12-11 | United Therapeutics Corporation | $4,212 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A MULTICENTER RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROST | 2019 |
| 2019-12-11 | United Therapeutics Corporation | $145 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DI | 2019 |
| 2019-12-10 | Celgene Corporation | $1,000 | Research payment | Cash or cash equivalent | Tislelizumab Drug | A PHASE 3, RANDOMIZED, BLINDED, PLACEBO-CONTROLLED STUDY OF TISLELIZUMAB (BGB-A317) PLUS CHEMORADIOTHERAPY FOLLOWED BY T | 2019 |
| 2019-12-10 | PFIZER INC. | $750 | Research payment | Cash or cash equivalent | A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG | 2019 | |
| 2019-12-10 | PFIZER INC. | $750 | Research payment | Cash or cash equivalent | A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG | 2019 | |
| 2019-12-09 | Incyte Corporation | $510 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-09 | Incyte Corporation | $321 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-09 | Incyte Corporation | $171 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-09 | Incyte Corporation | $148 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-09 | Incyte Corporation | $119 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-09 | Incyte Corporation | $107 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-09 | Incyte Corporation | $107 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-09 | Incyte Corporation | $81 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-09 | Incyte Corporation | $81 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-09 | Incyte Corporation | $81 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-09 | Incyte Corporation | $62 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-09 | Incyte Corporation | $62 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-09 | Incyte Corporation | $62 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-09 | Incyte Corporation | $51 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-09 | Incyte Corporation | $51 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-09 | Incyte Corporation | $51 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-09 | Incyte Corporation | $51 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-09 | Incyte Corporation | $51 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-09 | Incyte Corporation | $51 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-09 | Incyte Corporation | $30 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-09 | Incyte Corporation | $28 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-09 | Incyte Corporation | $1 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-06 | Medical Device Business Services, Inc. | $4,259 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi-Center Clinical Evaluation of the ATTUNE Revision System in Revision Total Knee Arthroplasty | 2019 |
| 2019-12-06 | W. L. Gore & Associates, Inc. | $1,375 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE EXCLUDER Iliac Branch Endoprosthesis for the Treatment of Common Iliac Artery Aneurysms or Aorto- | 2019 |
| 2019-12-05 | TESARO, Inc. | $14,500 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | CROSSOVER STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF NIRAPARIB TABLET COMPARED TO NIRAPARIB CAPSULE | 2019 |
| 2019-12-03 | Welch Allyn | $2,555 | Gift | Cash or cash equivalent | 2019 | ||
| 2019-12-03 | Intercept Pharmaceuticals, Inc. | $2,123 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-12-03 | GlaxoSmithKline, LLC. | $1,764 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P | 2019 | |
| 2019-12-03 | CVRx, Inc. | $750 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2019 | |
| 2019-12-03 | Incyte Corporation | $400 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-12-02 | PFIZER INC. | $5,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-12-02 | Astellas Pharma US Inc | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LEXISCAN Drug, CARDIOLOGY | 2019 | |
| 2019-12-02 | Boston Scientific Corporation | $1,271 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SMART MSP | 2019 |
| 2019-11-28 | Abbott Laboratories | $2,500 | Research payment | Cash or cash equivalent | Structural Heart Device, Cardiac Arrhythmias and Heart Failure | 15mm Surgical Mechanical Aortic Valve PAS | 2019 |
| 2019-11-27 | Barco, Inc. | $80 | Food and Beverage | Cash or cash equivalent | Diagnostic Displays Device, Diagnostic Imaging | 2019 | |
| 2019-11-25 | CVRx, Inc. | $500 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2019 | |
| 2019-11-20 | Gilead Sciences, Inc. | $1,998 | Research payment | Cash or cash equivalent | Cayston Drug, RESP | Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg | 2019 |
| 2019-11-19 | Incyte Corporation | $21,824 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-11-19 | PFIZER INC. | $750 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY O | 2019 | |
| 2019-11-18 | Medical Device Business Services, Inc. | $350 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi-Center Clinical Evaluation of the ATTUNE Revision System in Complex Primary Total Knee Arthroplasty | 2019 |
| 2019-11-14 | Allergan, Inc. | $5,725 | Research payment | Cash or cash equivalent | A Two-part, Multicenter, Dose-titration Study Evaluating the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of | 2019 | |
| 2019-11-13 | Hill-Rom Company, Inc | $5,129 | Travel and Lodging | In-kind items and services | Hill-Rom Heart and Respiration Rate Monitoring System powered by EarlySense Device, Breathing Frequency Monitor | 2019 | |
| 2019-11-13 | KLS-Martin L.P. | $2,500 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-11-13 | Hill-Rom Company, Inc | $2,062 | Travel and Lodging | In-kind items and services | Hill-Rom Heart and Respiration Rate Monitoring System powered by EarlySense Device, Breathing Frequency Monitor | 2019 | |
| 2019-11-13 | Hill-Rom Company, Inc | $1,973 | Food and Beverage | In-kind items and services | Hill-Rom Heart and Respiration Rate Monitoring System powered by EarlySense Device, Breathing Frequency Monitor | 2019 | |
| 2019-11-13 | Hill-Rom Company, Inc | $1,275 | Travel and Lodging | In-kind items and services | Hill-Rom Heart and Respiration Rate Monitoring System powered by EarlySense Device, Breathing Frequency Monitor | 2019 | |
| 2019-11-12 | PFIZER INC. | $7,415 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY O | 2019 | |
| 2019-11-12 | PFIZER INC. | $4,053 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY O | 2019 | |
| 2019-11-12 | ABBVIE INC. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Humira Biological, Immunology | 2019 | |
| 2019-11-11 | Janssen Research & Development, LLC | $16,000 | Research payment | Cash or cash equivalent | A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with | 2019 | |
| 2019-11-09 | Novartis Pharmaceuticals Corporation | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | 2019 | |
| 2019-11-08 | Incyte Corporation | $377 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-11-08 | Incyte Corporation | $124 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-11-08 | Incyte Corporation | $62 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-11-08 | Incyte Corporation | $0 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-11-07 | Incyte Corporation | $1,775 | Research payment | Cash or cash equivalent | A Randomized, Double Blind, Placebo Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroid | 2019 | |
| 2019-11-07 | Medical Device Business Services, Inc. | $1,473 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi-Center Clinical Evaluation of the ATTUNE Revision System in Complex Primary Total Knee Arthroplasty | 2019 |
| 2019-11-06 | LANTHEUS MEDICAL IMAGING, INC. | $1,191 | Gift | In-kind items and services | Ablavar Drug, Contrast Agent | 2019 | |
| 2019-11-05 | TESARO, Inc. | $1,000 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | CROSSOVER STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF NIRAPARIB TABLET COMPARED TO NIRAPARIB CAPSULE | 2019 |
| 2019-11-05 | Roche Products Limited | $177 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE | 2019 |
| 2019-11-04 | Boston Scientific Corporation | $674 | Research payment | Cash or cash equivalent | GENERAL TACHY Device, TACHY | LSS OF 4 SITE | 2019 |
| 2019-11-04 | Medical Device Business Services, Inc. | $500 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi-Center Clinical Evaluation of the ATTUNE Revision System in Complex Primary Total Knee Arthroplasty | 2019 |
| 2019-11-04 | Medical Device Business Services, Inc. | $100 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi-Center Clinical Evaluation of the ATTUNE Revision System in Revision Total Knee Arthroplasty | 2019 |
| 2019-11-01 | Helena Laboratories Corporation | $4 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-10-31 | Bayer Healthcare Pharmaceuticals Inc. | $1,700 | Research payment | Cash or cash equivalent | Non-Covered | Phase III RB/RCHOP +/- copanlisib in iNHL | 2019 |
| 2019-10-31 | Bayer Healthcare Pharmaceuticals Inc. | $1,000 | Research payment | Cash or cash equivalent | Non-Covered | Phase III RB/RCHOP +/- copanlisib in iNHL | 2019 |
| 2019-10-31 | Bayer Healthcare Pharmaceuticals Inc. | $1,000 | Research payment | Cash or cash equivalent | Non-Covered | Phase III RB/RCHOP +/- copanlisib in iNHL | 2019 |
| 2019-10-23 | AstraZeneca Pharmaceuticals LP | $27,930 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclon | 2019 | |
| 2019-10-23 | Gilead Sciences, Inc. | $4,220 | Research payment | Cash or cash equivalent | Cayston Drug, RESP | Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg | 2019 |
| 2019-10-23 | MED-EL Corporation | $500 | Research payment | Cash or cash equivalent | MED-EL Maestro Cochlear Implant System Device, Cochlear implant | Expanded Indications in the MED-EL pediatric Cochlear Implant population | 2019 |
| 2019-10-22 | LivaNova USA, Inc. | $5,541 | Research payment | Cash or cash equivalent | VNS Therapy Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2019 |
| 2019-10-21 | AstraZeneca Pharmaceuticals LP | $22,984 | Research payment | Cash or cash equivalent | A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Anti | 2019 | |
| 2019-10-17 | Abbott Laboratories | $6,500 | Research payment | Cash or cash equivalent | Structural Heart Device, Cardiac Arrhythmias and Heart Failure | 15mm Surgical Mechanical Aortic Valve PAS | 2019 |
| 2019-10-17 | Medical Device Business Services, Inc. | $4,950 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi-Center Clinical Evaluation of the ATTUNE Revision System in Complex Primary Total Knee Arthroplasty | 2019 |
| 2019-10-17 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus | 2019 | |
| 2019-10-14 | Linvatec Corporation | $2,554 | Grant | In-kind items and services | AIRSEAL Device, GENERAL SURGERY | 2019 | |
| 2019-10-14 | Medical Device Business Services, Inc. | $1,600 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi-Center Clinical Evaluation of the ATTUNE Revision System in Revision Total Knee Arthroplasty | 2019 |
| 2019-10-10 | Baxter Healthcare | $10,349 | Research payment | Cash or cash equivalent | Renal - Amia Device, Renal | Performance Evaluation of the AMIA Automated Peritoneal Dialysis -APD- Solution Generation System in Patients Using the | 2019 |
| 2019-10-10 | Intercept Pharmaceuticals, Inc. | $6,661 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-10-10 | GENZYME CORPORATION | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | THYMOGLOBULIN Drug, ONCOLOGY | 2019 | |
| 2019-10-10 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RELISTOR Drug, GASTROENTEROLOGY | 2019 | |
| 2019-10-09 | KARL STORZ Endoscopy-America | $780 | Gift | In-kind items and services | ADAPTOR, C-MOUNT, 30MM, CE, F/HEAD&NECK Device, VIDEOIMAGING | 2019 | |
| 2019-10-09 | KARL STORZ Endoscopy-America | $120 | Gift | In-kind items and services | TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY | 2019 | |
| 2019-10-09 | Stryker Corporation | $66 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $10 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-08 | Incyte Corporation | $377 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-10-08 | Incyte Corporation | $377 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-10-08 | Incyte Corporation | $124 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-10-08 | Incyte Corporation | $61 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-10-08 | Incyte Corporation | $38 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-10-08 | Incyte Corporation | $30 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-10-08 | Incyte Corporation | $19 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-10-07 | Boston Scientific Corporation | $1,239 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SMART MSP | 2019 |
| 2019-10-06 | KARL STORZ Endoscopy-America | $193 | Education | In-kind items and services | TROCAR & CANNULA,W/MULTI- Device, LAPAROSCOPY | 2019 | |
| 2019-10-03 | Incyte Corporation | $30,039 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-09-27 | Merck Sharp & Dohme LLC | $5,028 | Research payment | Cash or cash equivalent | MK-1242 Drug, CARDIOVASCULAR | A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical out | 2019 |
| 2019-09-25 | AstraZeneca Pharmaceuticals LP | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BRILINTA Drug, Cardiovascular and Metabolism | 2019 | |
| 2019-09-25 | United Therapeutics Corporation | $107 | Research payment | In-kind items and services | TYVASO Drug, PAH | AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DI | 2019 |
| 2019-09-24 | Zimmer Biomet Holdings, Inc. | $2,000 | Grant | Cash or cash equivalent | CMF Non Device, CMF & Thoracic | 2019 | |
| 2019-09-19 | Shire North American Group Inc | $38,762 | Research payment | Cash or cash equivalent | A PHASE 2B, MULTICENTER, RANDOMIZED, OPEN-LABEL, CONTROLLED, 3-ARM STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF | 2019 | |
| 2019-09-19 | Shire North American Group Inc | $35,495 | Research payment | Cash or cash equivalent | A PHASE 2B, MULTICENTER, RANDOMIZED, OPEN-LABEL, CONTROLLED, 3-ARM STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF | 2019 | |
| 2019-09-19 | Shire North American Group Inc | $34,279 | Research payment | Cash or cash equivalent | A PHASE 2B, MULTICENTER, RANDOMIZED, OPEN-LABEL, CONTROLLED, 3-ARM STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF | 2019 | |
| 2019-09-19 | PFIZER INC. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-09-18 | Gilead Sciences, Inc. | $1,422 | Research payment | Cash or cash equivalent | Cayston Drug, RESP | Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg | 2019 |
| 2019-09-18 | Stryker Corporation | $25 | Grant | Cash or cash equivalent | NONE Device, NONE | 2019 | |
| 2019-09-17 | LivaNova USA, Inc. | $4,152 | Research payment | Cash or cash equivalent | VNS Therapy Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2019 |
| 2019-09-13 | W. L. Gore & Associates, Inc. | $6,877 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Gore Research and Development | 2019 |
| 2019-09-13 | Novartis Pharmaceuticals Corporation | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-09-12 | Intercept Pharmaceuticals, Inc. | $1,892 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-09-12 | PFIZER INC. | $400 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY O | 2019 | |
| 2019-09-11 | United Therapeutics Corporation | $300 | Research payment | Cash or cash equivalent | REMODULIN Drug, PAH | INTRAVENOUS REMODULIN TREPROSTINIL AS ADD-ON THERAPY FOR THE TREATMENT OF PERSISTENT PULMONARY HYPERTENSION OF THE NEWBO | 2019 |
| 2019-09-11 | United Therapeutics Corporation | $145 | Research payment | In-kind items and services | TYVASO Drug, PAH | AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DI | 2019 |
| 2019-09-10 | Incyte Corporation | $52,638 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-09-10 | Incyte Corporation | $29,376 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-09-10 | Incyte Corporation | $7,754 | Research payment | Cash or cash equivalent | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | 2019 | |
| 2019-09-10 | Merck Sharp & Dohme LLC | $650 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ISENTRESS Drug, INFECTIOUS DISEASE | 2019 | |
| 2019-09-09 | Merck Sharp & Dohme LLC | $751 | Research payment | Cash or cash equivalent | MK-1242 Drug, CARDIOVASCULAR | A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical out | 2019 |
| 2019-09-05 | PFIZER INC. | $2,184 | Research payment | Cash or cash equivalent | AN OPENLABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF RIVIPANSEL GMI1070 IN THE TREATMENT OF ONE OR MORE VASOOCCLUSIVE | 2019 | |
| 2019-09-05 | PFIZER INC. | $400 | Research payment | Cash or cash equivalent | AN OPENLABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF RIVIPANSEL GMI1070 IN THE TREATMENT OF ONE OR MORE VASOOCCLUSIVE | 2019 | |
| 2019-09-05 | PFIZER INC. | $100 | Research payment | Cash or cash equivalent | AN OPENLABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF RIVIPANSEL GMI1070 IN THE TREATMENT OF ONE OR MORE VASOOCCLUSIVE | 2019 | |
| 2019-09-04 | Gilead Sciences, Inc. | $750 | Research payment | Cash or cash equivalent | Cayston Drug, RESP | Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg | 2019 |
| 2019-09-02 | PFIZER INC. | $15,070 | Research payment | In-kind items and services | ZAVICEFTA NEONATAL SEPSIS TRIAL | 2019 | |
| 2019-09-02 | Medical Device Business Services, Inc. | $4,126 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi-Center Clinical Evaluation of the ATTUNE Revision System in Revision Total Knee Arthroplasty | 2019 |
| 2019-09-01 | VERTEX PHARMACEUTICALS INCORPORATED | $15,037 | Research payment | Cash or cash equivalent | A Study Evaluating the Long-term Safety of VX-445 Combination Therapy | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $3,440 | Education | In-kind items and services | AUTOCON II 400 HIGH END UNIT W/PWR CORD Device, OTHER MISC | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $3,318 | Education | In-kind items and services | TELE PACK X, CCU/LIGHT SOURCE/MONITOR Device, VIDEOIMAGING | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $825 | Education | In-kind items and services | TELESCOPE,HOPKINS II,AUTOCLAVABLE Device, LAPAROSCOPY | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $825 | Education | In-kind items and services | TELESCOPE,HOPKINS II,AUTOCLAVABLE Device, LAPAROSCOPY | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $815 | Education | In-kind items and services | TELESCOPE, HOPKINS,30'AUTOCLAVABLE Device, GYNECOLOGY | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $729 | Education | In-kind items and services | HD,TELECAM-C'MT, NTSC, CE Device, VIDEOIMAGING | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $377 | Education | In-kind items and services | ROBI HANDLE, LARGER CONTACT AREA Device, LAPAROSCOPY | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $323 | Education | In-kind items and services | ENDOSCOPIC SURGERY TRAINER,SET, Device, GYNECOLOGY | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $314 | Education | In-kind items and services | ROBI FORCEPS, CLERMONT-FERRAND, KIT Device, LAPAROSCOPY | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $282 | Education | In-kind items and services | TROCAR, SIZE 6MM Device, LAPAROSCOPY | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $281 | Education | In-kind items and services | NEEDLE HOLDER, 'KOH', MACRO Device, LAPAROSCOPY | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $281 | Education | In-kind items and services | NEEDLE HOLDER, 'KOH', MACRO Device, LAPAROSCOPY | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $281 | Education | In-kind items and services | KOH ASSISTANT NEEDLE HOLDER, PISTOL GRIP Device, LAPAROSCOPY | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $272 | Education | In-kind items and services | 5MM HYSTEROSCOPE SHEATH, 1 PC DESIGN Device, GYNECOLOGY | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $195 | Education | In-kind items and services | CLICKLINE 'METZENBAUM' SCISSORS Device, LAPAROSCOPY | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $195 | Education | In-kind items and services | CLICKLINE,REDDICK-OLSEN, DISSECTING AND Device, LAPAROSCOPY | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $195 | Education | In-kind items and services | CLICKLINE 'KELLY' GRASP FORCEPS Device, LAPAROSCOPY | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $188 | Education | In-kind items and services | HESSELING FORCEPS 5 Fr. Device, GYNECOLOGY | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $188 | Education | In-kind items and services | FORCEPS,BIOPSY/GRASPING,HORIZ Device, GYNECOLOGY | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $188 | Education | In-kind items and services | SCISSORS,HORIZ CUT,RIGHT,SNGL Device, GYNECOLOGY | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $162 | Education | In-kind items and services | ADAPTOR, C'MT, 30MM, CE Device, VIDEOIMAGING | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $156 | Education | In-kind items and services | CLICKLINE ROBI CLERMONT-FERRAND GRSP FCP Device, LAPAROSCOPY | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $132 | Education | In-kind items and services | LIGHT CABLE, 3.5MM X 300CM. LGTH 9.8 FT Device, VIDEOIMAGING | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $128 | Education | In-kind items and services | CLICKLINE ROBI CLERMONT-FERRAND GRSP FCP Device, LAPAROSCOPY | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $73 | Education | In-kind items and services | CORD,HIGH FREQUENCY,BIPOLAR Device, OTHER MISC | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $70 | Education | In-kind items and services | KNOT TIER Device, LAPAROSCOPY | 2019 | |
| 2019-08-28 | KARL STORZ Endoscopy-America | $50 | Education | In-kind items and services | 1.2MM SELF SEALING SEAL FOR GYNECOLOGY Device, GYNECOLOGY | 2019 | |
| 2019-08-24 | Alcon Vision LLC | $3,000 | Education | In-kind items and services | 2019 | ||
| 2019-08-24 | Alcon Vision LLC | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-08-24 | Allergan, Inc. | $1,000 | Education | Cash or cash equivalent | 2019 | ||
| 2019-08-21 | LivaNova USA, Inc. | $35,645 | Research payment | Cash or cash equivalent | VNS Therapy Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2019 |
| 2019-08-21 | KLS-Martin L.P. | $2,500 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-08-21 | Gilead Sciences, Inc. | $1,998 | Research payment | Cash or cash equivalent | Cayston Drug, RESP | Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg | 2019 |
| 2019-08-21 | Barco, Inc. | $31 | Food and Beverage | Cash or cash equivalent | Diagnostic Displays Device, Diagnostic Imaging | 2019 | |
| 2019-08-20 | Dentsply Sirona Inc | $2,099 | Grant | Cash or cash equivalent | MIDWEST Accessories Device, Restorative Dentistry | 2019 | |
| 2019-08-20 | Dentsply Sirona Inc | $1,643 | Grant | Cash or cash equivalent | MIDWEST Accessories Device, Restorative Dentistry | 2019 | |
| 2019-08-20 | Emmaus Medical, Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Endari Drug, Sickle Cell | 2019 | |
| 2019-08-19 | MED-EL Corporation | $75,850 | Research payment | In-kind items and services | MED-EL Maestro Cochlear Implant System Device, Cochlear implant | Expanded Indications in the MED-EL pediatric Cochlear Implant population | 2019 |
| 2019-08-19 | E.R. Squibb & Sons, L.L.C. | $20,500 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate | 2019 | |
| 2019-08-19 | Boston Scientific Corporation | $2,644 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SMART MSP | 2019 |
| 2019-08-19 | CVRx, Inc. | $810 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2019 | |
| 2019-08-19 | E.R. Squibb & Sons, L.L.C. | $750 | Research payment | Cash or cash equivalent | Multiple Ascending Dose - Solid Tumors | 2019 | |
| 2019-08-15 | E.R. Squibb & Sons, L.L.C. | $20,000 | Grant | Cash or cash equivalent | 2019 |
The latest 200 records of 581.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Jackson, MS, county Hinds County, MS, state Mississippi; placed by its city name.
| Measure | Place (city or town) Jackson, MS | County Hinds County, MS | State Mississippi |
|---|---|---|---|
| Population B01003 | 146,631 | 218,533 | 2,946,779 |
| Population, 2020 census P1 | 153,701 | 227,742 | 2,961,279 |
| Median age B01002 | 34.5 | 36.9 | 38.6 |
| Under 18 B01001 | 23.9% | 23.5% | 23.3% |
| 65 and over B01001 | 15.0% | 16.3% | 17.2% |
| Households B11001 | 61,415 | 89,578 | 1,145,431 |
| Foreign born B05002 | 1.6% | 2.0% | 2.4% |
| Median household income B19013 | $42,071 | $49,402 | $56,447 |
| Median family income B19113 | $52,810 | $64,969 | $73,163 |
| Per capita income B19301 | $26,811 | $29,530 | $31,549 |
| Poverty rate B17001 | 27.9% | 22.7% | 18.9% |
| Unemployment rate B23025 | 9.3% | 7.5% | 5.8% |
| Civilian labor force B23025 | 69,393 | 102,828 | 1,332,121 |
| Mean commute (minutes) B08013 | 19.9 | 22.3 | 25.6 |
| Bachelor's degree or higher B15003 | 28.8% | 31.2% | 25.1% |
| Housing units B25001 | 74,871 | 106,340 | 1,341,114 |
| Owner-occupied B25003 | 48.6% | 58.3% | 70.0% |
| Renters B25003 | 51.4% | 41.7% | 30.0% |
| Median home value B25077 | $111,700 | $159,900 | $169,800 |
| Median gross rent B25064 | $1,055 | $1,061 | $954 |
| White, not Hispanic B03002 | 13.3% | 22.9% | 55.2% |
| Black B03002 | 81.7% | 71.7% | 36.3% |
| Hispanic or Latino B03002 | 2.4% | 2.1% | 3.7% |
| Asian B03002 | 0.3% | 0.8% | 1.0% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.4% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Jackson, MS.
Comments